Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tobacco law drives lawsuits from tobacco firms

This article was originally published in The Tan Sheet

Executive Summary

The law passed in June requiring FDA to regulate tobacco products sparks a lawsuit against the agency by tobacco manufacturers (1"The Tan Sheet" June 15, 2009). The lawsuit, filed Aug. 31 in U.S. District Court in Bowling Green, Ky., alleges some of the Family Smoking Prevention and Tobacco Control Act's provisions violate First Amendment rights by, for example, restricting manufacturers' communication with adult tobacco users and requiring sizeable warning labels, which will reduce space for product labels. The second-largest tobacco firm, Reynolds American Inc., joined the complaint, but market leader Philip Morris USA, which supported the law, is not party to the suit

You may also be interested in...



Tight 90-Day Countdown To Create Tobacco Center Poses Challenge To FDA

FDA has its work cut out for it to establish a Center for Tobacco Products within 90 days, once President Obama adds his promised signature to the bill giving the agency regulatory authority over tobacco

Biocon Biologics Refreshes Management

Biocon has made two key appointments to the management team of Biocon Biologics following a recent change in CEO for the biosimilars business.

Optibac Launches Natural Children’s Probiotic Immunity Supplement In Sustainable Pack

The UK's Optibac responds to sustainability and naturals trends with an all-in-one immunity and gut health food supplement especially designed for children.

Topics

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel